Tobacco use is the leading cause of preventable death in the world. Although cigarette smoking prevalence has decreased, there are still disparities in morbidity and mortality experienced by individuals with substance use and/or mental disorders when compared to general population. The aim of this study was to compare treatment outcomes between three subgroups of smokers: individuals with substance use disorder (SUD-only), individuals with mental disorder without substance use disorders (MD-only), and individuals with co-morbid substance use and mental disorder (SUD + MD). Data of 498 smokers enrolled in a 6-week smoking cessation program in Brazil were analyzed. Sociodemographic, medical and tobacco use information were collected at baseline. Treatment included group cognitive behavioral therapy (CBT) and pharmacotherapy. The primary outcome was defined as "self-report 4-week quitter" (SR4WQ), a standardized measure to assess treatment success. Retention to treatment was also investigated. Associations between groups were analyzed using unadjusted and adjusted logistic regression models. The results showed that SUD + MD had worse outcomes when compared to the other two groups. After adjusting for level of smoking dependence and the use of medication, abstinence and retention to treatment of SUD-only became equivalent to SUD + MD. Because tobacco and other substance addictions share similar mechanisms, having history of SUD might impair successful results of conventional smoking programs. There is a need to further investigate specific variables associated with treatment success for a more resistant subgroup of individuals in mental health and perhaps to invest in more intensive actions, such as the use of combined pharmacotherapy and adapted CBT approaches.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpsychires.2020.03.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Contingency management (CM), an evidence-based behavioral strategy that rewards positive behavior change including tobacco cessation, is rarely offered to support people with HIV (PWH) who smoke. In this study, we explored perspectives among patients and research staff engaged in a multi-site randomized clinical trial involving clinical pharmacist-delivered CM within HIV clinics. Between February and September 2023, we conducted 1:1 interviews with 12 PWH randomized to receive CM and one focus group with 8 staff (i.
View Article and Find Full Text PDF"I still can feel the sickness": Withdrawal experiences of people on methadone maintenance treatment.
J Subst Use Addict Treat
December 2024
Department of Social and Behavioral Sciences, School of Global Public Health, New York University, New York, NY 10003, USA; Center for Drug Use and HIV/HCV Research, School of Global Public Health, New York University, New York, NY 10003, USA.
Introduction: Opioid withdrawal is a regular occurrence for many people who use illicit opioids (PWUIO) involving acute physical and psychological pain. Yet, there is very little data on the withdrawal experience of people in methadone maintenance treatment (MMT) and almost none from the patients' experience. Learning more about patients' withdrawal experiences can help to inform policies and practices that are better suited to address withdrawal and may improve patient satisfaction as well as uptake and retention.
View Article and Find Full Text PDFA proof-of-concept trial of a smoking cessation and anxiety sensitivity reduction smartphone application for Black adults.
Cogn Behav Ther
November 2024
TSET Health Promotion Research Center, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, 655 Research Parkway, Oklahoma City, OK, USA.
Article Synopsis
- - Black individuals who smoke experience higher rates of tobacco-related health issues, which are influenced by stress related to their minority status and anxiety sensitivity (AS).
- - A study tested a smartphone app, the Mobile Anxiety Sensitivity Program for Smoking (MASP), designed to help Black smokers with high AS quit smoking and reduce their AS.
- - The trial with 24 participants showed high app usage, excellent retention, good participant feedback, and a significant reduction in anxiety sensitivity, with 25% of participants achieving short-term smoking abstinence.
Therapeutic experience with tramadol for opioid dependence: A prospective observational study from India.
J Opioid Manag
November 2024
National Drug Dependence Treatment Centre (NDDTC); Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Introduction: Opioid use disorder (OUD) is a chronic relapsing disorder with significant mortality, morbidity, and public health challenges. In India, tramadol is frequently used for the treatment and management of OUDs.
Methodology: A prospective observational study was performed to evaluate 3-month outcomes in outpatients with OUD on treatment with tramadol at a tertiary care addiction treatment facility in North India.
Tobacco Quitline Retreatment Interventions Among Adults With Socioeconomic Disadvantage: A Factorial Randomized Clinical Trial.
JAMA Netw Open
November 2024
Center for Tobacco Research and Intervention, University of Wisconsin School of Medicine and Public Health, Madison.
Importance: A single round of standard tobacco quitline treatment may not be sufficient to sustain abstinence, particularly among people experiencing socioeconomic disadvantage. Adaptive retreatment may help more individuals with socioeconomic disadvantage achieve abstinence and reduce disparities in smoking cessation outcomes.
Objective: To evaluate 4 evidence-based strategies for adults with limited education, no insurance, or Medicaid eligibility who continued smoking after quitline treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!